Mene Pangalos, AstraZeneca EVP of BioPharmaceuticals R&D (AstraZeneca via YouTube)
In new deal, AstraZeneca places small bet on 'critical but challenging' target
AstraZeneca has its eyes on NRF2 as a target for inflammatory and respiratory diseases, and it’s handing out $2 million in cash to pluck a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
